Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

NCT01676220 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

878

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: HOE901-U300 (new formulation of insulin glargine)
DRUG: Lantus (insulin glargine)

Sponsor

Sanofi